Michael J. Donnelly v. Keryx Biopharmaceuticals, Inc.

CourtCourt of Chancery of Delaware
DecidedOctober 24, 2019
DocketCA No. 2018-0892-SG
StatusPublished

This text of Michael J. Donnelly v. Keryx Biopharmaceuticals, Inc. (Michael J. Donnelly v. Keryx Biopharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Michael J. Donnelly v. Keryx Biopharmaceuticals, Inc., (Del. Ct. App. 2019).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

MICHAEL J. DONNELLY, ) ) Plaintiff, ) ) ) v. ) C.A. No. 2018-0892-SG ) KERYX BIOPHARMACEUTICALS, ) INC., ) ) Defendant. ) )

MEMORANDUM OPINION

Date Submitted: July 10, 2019 Date Decided: October 24, 2019

Peter B. Andrews, Craig J. Springer, and David M. Sborz, of ANDREWS & SPRINGER LLC, Wilmington, Delaware; OF COUNSEL: Randall J. Baron, David T. Wissbroecker, and Christopher H. Lyons, of ROBBINS GELLER RUDMAN & DOWD LLP, San Diego, California and Nashville, Tennessee, Attorneys for Plaintiff.

David E. Ross and S. Michael Sirkin, of ROSS ARONSTAM & MORITZ LLP, Wilmington, Delaware; OF COUNSEL: Peter L. Welsh, Christian Reigstad, and Mary Zou, of ROPES & GRAY LLP, New York, New York, Attorneys for Defendant.

GLASSCOCK, Vice Chancellor What follows is, for me at least, a rare bird; a written Section 220 decision.

This Memorandum Opinion addresses Plaintiff’s Section 220 demand for books and

records from Keryx Biopharmaceuticals, Inc. (“Defendant” or “Keryx”) related to

its 2018 merger with Akebia Therapeutics, Inc. (“Akebia”). The Plaintiff seeks

books and records relevant to alleged breaches of the duty of loyalty and improper

disclosure. The Defendant asserts that the Plaintiff’s purpose is pretextual,1

requiring dismissal under the rationale of Wilkinson v. A. Schulman, Inc.2 The

Plaintiff, in turn, asks me to find that the Defendant has opposed its document

demand in bad faith, and to shift attorney’s fees accordingly. Because these issues

seemed best addressed in writing, this Memorandum Opinion has followed. For the

reasons stated below, I grant the Plaintiff’s 220 demand. I do not find bad faith and

accordingly do not shift attorney’s fees.

I. BACKGROUND

What follows is an adumbration of the facts sufficient to the issues before me.

Keryx, a Delaware corporation, is a commercial stage biopharmaceutical company

that develops and markets medicines for kidney disease.3 Its marketed product,

Auryxia, is approved by the FDA and is also available in Japan and Europe. 4 Prior

1 The Defendant also disputes that the Plaintiff has shown a credible basis to imply wrongdoing. 2 2017 WL 5289553 (Del. Ch. Nov. 13, 2017). 3 Joint Pre-Trial Stipulation and Order (“Pre-Trial Order”) ¶ 1; JX 5, at 5; JX 8, at 26. 4 JX 5, at 5; JX 8, at 26. to Keryx’s merger with Akebia, Baupost Group Securities, L.L.C. (“Baupost”) was

Keryx’s largest stockholder, with an approximate 21.4% stake of outstanding Keryx

common stock.5 Baupost also held approximately $164.75 million of Keryx’s senior

notes, which were convertible into common stock.6 If converted, the notes would

give Baupost approximately a 39% ownership stake.7 Keryx listed Baupost in its

10-K as its largest stockholder and one that “through its equity interests, may have

significant influence over matters submitted to [Keryx’s] stockholders for approval

and other corporate actions. . . .” 8 In addition to its ownership interest, Baupost had

a contractual right to appoint one director and one observer to Keryx’s seven-director

board (the “Board”).9

In September 2017, John Butler—Akebia’s President and CEO—resigned as

Baupost’s appointee on the Keryx Board.10 That month, Baupost replaced Butler

5 JX 8, at 17, 189-90. 6 JX 8, 79–80, 189–90. 7 JX 5, at 38. 8 Id. 9 JX 1, at 149–50, 156; JX 7, at 18. 10 JX 7, at 13, 18, 46; JX 3, at 1–2. The parties disagree about whether Butler was CEO of Akebia and Chairman of Keryx simultaneously. The press announcement regarding Enyedy’s appointment indicates that Butler was “chairman of the Keryx board of directors and president and chief executive officer of Akebia Therapeutics, Inc.” JX 3, at 1. Keryx’s counsel, however, represented at trial that there was no overlap between these positions. Trial Tr. 63:21–64:5.

2 with a new director, Mark Enyedy. 11 The remainder of the Board, with the exception

of then-CEO Greg Madison, were non-management, outside directors.12

In December 2017, the Board formed a special committee (the “Committee”),

chaired by Baupost’s appointee, Enyedy, to explore a merger with Akebia, as well

as other potential alternatives. 13 The Committee hired Perella Weinberg Partners as

a financial advisor and engaged in discussions with Akebia and two other parties

based on a review of eight potential strategic partners or acquirers.14 During this

process, Keryx communicated with Baupost to ensure its support.15 In early

February 2018, Keryx, at the Committee’s recommendation, declined to go forward

with Akebia, citing concerns with Akebia’s development stage, the timing of its

clinical program, and the companies’ respective balance sheets and cash positions. 16

Discussions between Keryx and Akebia ceased. 17

Shortly thereafter, Keryx reopened explorations in a broader field.18 It

engaged a new financial advisor, MTS Health Partners (“MTS”), and the Committee

11 JX 7, at 13, 18, 46; JX 3, at 1–2. 12 JX 7, at 12. 13 JX 8, at 82. 14 Id. at 80. 15 Id. 16 Id. at 84. 17 Id. 18 Id. at 84–85.

3 authorized management to enter preliminary discussions with a broad range of

potential partners.19 The Committee engaged with several parties, but none was

interested in an acquisition of or merger with Keryx. 20

While Keryx was exploring these options in March 2018, and at a time shortly

after Keryx’s board had determined that a merger with Akebia was not in Keryx’s

interest, Baupost conducted its own due diligence on Akebia.21 Then, in late April,

Madison resigned from his position as CEO of Keryx, and the Board appointed Jodie

Morrison as interim CEO. 22 At the same board meeting, Baupost provided Keryx

with access to its due diligence on Akebia.23 The Board directed Morrison to inquire

whether Akebia would be interested in reengaging in discussions regarding a

potential transaction.24 Recognizing certain conflicts, the Board re-constituted the

Committee, this time with CEO Morrison as chairman, alongside two independent,

non-management directors.25 Over the next two months, Keryx and Akebia engaged

in due diligence and merger negotiations.26

19 Id. at 84. 20 Id. at 85. 21 Id. 22 Id.; JX 6. 23 JX 8, at 85. 24 Id. 25 Id. at 86. 26 Id. at 85–93.

4 As a part of the discussions, Keryx and Akebia also engaged with Baupost

concerning early conversion of Baupost’s senior notes.27 Baupost requested

consideration, and the parties ultimately formed an agreement under which Baupost

received four million additional shares of common stock, valued at approximately

$20 million, in exchange for early conversion of its notes.28

In addition, several Keryx officers received monetary or employment benefits

related to the transaction. On May 1, 2018, with merger negotiations in their nascent

stages, Keryx entered into retention agreements with three named executives

(besides Morrison) adding an approximate combined $450,000 in single-trigger

bonuses for a change-of-control. 29 Morrison’s term as interim CEO was originally

set to expire on October 31, 2018, but she entered an employment agreement to

remain through the earlier of the close of the merger or the end of the year. 30 Under

the terms of her extended employment agreement, Morrison received a $150,000

cash payment in October for her “considerable efforts” since her hiring in May, as

well as a potential $200,000 cash retention payment upon closing. 31 Morrison and

27 Id. at 86–91. 28 Id. at 88–91. 29 Id. at 140–42.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Grimes v. DSC Communications Corp.
724 A.2d 561 (Court of Chancery of Delaware, 1998)
McGowan v. Empress Entertainment, Inc.
791 A.2d 1 (Court of Chancery of Delaware, 2000)
Seinfeld v. Verizon Communications, Inc.
909 A.2d 117 (Supreme Court of Delaware, 2006)
Patrick v. State
922 A.2d 415 (Supreme Court of Delaware, 2007)
Saito v. McKesson HBOC, Inc.
806 A.2d 113 (Supreme Court of Delaware, 2002)
Security First Corp. v. U.S. Die Casting & Development Co.
687 A.2d 563 (Supreme Court of Delaware, 1997)
Thomas & Betts Corp. v. Leviton Manufacturing Co.
681 A.2d 1026 (Supreme Court of Delaware, 1996)
Pershing Square v. Ceridian Corporation
923 A.2d 810 (Court of Chancery of Delaware, 2007)
Highland Select Equity Fund, L.P. v. Motient Corp.
906 A.2d 156 (Court of Chancery of Delaware, 2006)
Corwin v. KKR Financial Holdings LLC
125 A.3d 304 (Supreme Court of Delaware, 2015)
Amalgamated Bank v. Yahoo! Inc.
132 A.3d 752 (Court of Chancery of Delaware, 2016)
KT4 Partners LLC v. Palantir Technologies, Inc.
203 A.3d 738 (Supreme Court of Delaware, 2019)
Central Laborers Pension Fund v. News Corp.
45 A.3d 139 (Supreme Court of Delaware, 2012)
In re Morton's Restaurant Group, Inc. Shareholders Litigation
74 A.3d 656 (Court of Chancery of Delaware, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Michael J. Donnelly v. Keryx Biopharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/michael-j-donnelly-v-keryx-biopharmaceuticals-inc-delch-2019.